Lansky Play-Performance Scale for Pediatric Functional Status
Uses parent description of child’s activity to assess ability and response to treatment.
114 entries · Page 3 of 4
Uses parent description of child’s activity to assess ability and response to treatment.
Predicts survival in patients with malignant pleural effusion.
Determines if pleural fluid is exudative or transudative.
Predicts risk of liver decompensation after hepatectomy for hepatocellular carcinoma (HCC).
Predicts 2 year survival of small cell lung cancer.
Predicts survival in patients with mantle cell lymphoma.
Identifies patients at low risk for poor outcome with febrile neutropenia.
Calculates amount of RhIG to be administered to the mother, at the time of delivery, to prevent hemolytic disease of the fetus and newborn (HDFN).
Predicts metastatic renal cell carcinoma survival, more accurately than the Motzer Score.
Predicts survival based on clinical and laboratory data in metastatic RCC patients.
Predicts survival for patients with HCC.
Assess suitability of patients for liver transplant with cirrhosis and hepatocellular carcinoma, recommended by AASLD guidelines .
Provides improved cancer prognosis over the original score , based on serum biomarkers.
Measures treatment response, specifically to cytotoxic drugs, based on tumor shrinkage.
Diagnoses multiple myeloma, according to the International Myeloma Working Group (IMWG).
Prognosticates the severity of multiple myeloma based on routinely obtained lab values.
Predicts disease response in multiple myeloma, from the International Myeloma Working Group (IMWG).
Estimates the volume of whole blood to remove and volume of crystalloid to infuse in neonatal polycythemia.
Predicts postoperative pancreatic fistula, based on intraoperative findings, after pancreatic resection.
Calculates the pediatric version of the MELD score for liver cirrhosis severity and transplant planning.
Rules out PE if no criteria are present and pre-test probability is ≤15%.
Estimates CD34+ yield using pre-apheresis peripheral blood absolute CD34 blood count.
Predicts ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura (TTP) with high discrimination.
Predicts mortality for cancer patients with PE.
Predicts overall survival in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Predicts cancer mortality from serum biomarkers.
Predicts 3-month mortality in patients with malignant pleural effusion.
No entries match your filter.